Paltoglou S, Roberts BJ (2007) HIF-1alpha and EPAS ubiquitination mediated by the VHL tumour suppressor involves flexibility in the ubiquitination mechanism, similar to other RING E3 ligases. Oncogene 26, 604-9 16862177

This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.

Click on the protein name to open the protein page, and on the RSD number to open the site page.

Download

K532-ub - HIF1A (human) ▲

Modsite: SDMVNEFkLELVEkL SwissProt Entrez-Gene Orthologous residues HIF1A (human): K532‑ub, HIF1A (mouse): K545‑ub, HIF1A (rat): K531‑ub Characterization Methods used to characterize site in vivo:  electrophoretic mobility shift, mutation of modification site, western blotting Relevant cell lines - cell types - tissues:  HEK293T (epithelial), HeLa (cervical) Cellular systems studied:  cell lines Species studied:  human Enzymes shown to modify site in vitro:  Type Enzyme UBIQUITIN LIGASE UBE2D1 (human) UBIQUITIN LIGASE VHL (human) Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes UBIQUITIN LIGASE VHL (human) transfection of wild-type enzyme Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes hypoxia/reoxygenation increase Downstream Regulation Effect of modification (function):  protein degradation

K538-ub - HIF1A (human) ▲

Modsite: FkLELVEkLFAEDTE SwissProt Entrez-Gene Orthologous residues HIF1A (human): K538‑ub, HIF1A (mouse): K551‑ub, HIF1A (rat): K537‑ub Characterization Methods used to characterize site in vivo:  electrophoretic mobility shift, mutation of modification site, western blotting Relevant cell lines - cell types - tissues:  HEK293T (epithelial), HeLa (cervical) Cellular systems studied:  cell lines Species studied:  human Enzymes shown to modify site in vitro:  Type Enzyme UBIQUITIN LIGASE VHL (human) UBIQUITIN LIGASE UBE2D1 (human) Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes UBIQUITIN LIGASE VHL (human) transfection of wild-type enzyme Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes hypoxia/reoxygenation increase Downstream Regulation Effect of modification (function):  protein degradation

K547-ub - HIF1A (human) ▲

Modsite: FAEDTEAkNPFsTQD SwissProt Entrez-Gene Orthologous residues HIF1A (human): K547‑ub, HIF1A (mouse): K560‑ub, HIF1A (rat): K546‑ub Characterization Methods used to characterize site in vivo:  electrophoretic mobility shift, mutation of modification site, western blotting Relevant cell lines - cell types - tissues:  HEK293T (epithelial), HeLa (cervical) Cellular systems studied:  cell lines Species studied:  human Enzymes shown to modify site in vitro:  Type Enzyme UBIQUITIN LIGASE VHL (human) UBIQUITIN LIGASE UBE2D1 (human) Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes UBIQUITIN LIGASE VHL (human) transfection of wild-type enzyme Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes hypoxia/reoxygenation increase Downstream Regulation Effect of modification (function):  protein degradation

K497-ub - HIF2A (human) ▲

Modsite: TSLDNDLkIEVIEkL SwissProt Entrez-Gene Orthologous residues HIF2A (human): K497‑ub, HIF2A (mouse): K496‑ub, HIF2A (rat): K496‑ub Characterization Methods used to characterize site in vivo:  electrophoretic mobility shift, mutation of modification site, western blotting Relevant cell lines - cell types - tissues:  HEK293T (epithelial), HeLa (cervical) Cellular systems studied:  cell lines Species studied:  human Enzymes shown to modify site in vitro:  Type Enzyme UBIQUITIN LIGASE UBE2D1 (human) UBIQUITIN LIGASE VHL (human) Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes UBIQUITIN LIGASE VHL (human) transfection of wild-type enzyme

K503-ub - HIF2A (human) ▲

Modsite: LkIEVIEkLFAMDTE SwissProt Entrez-Gene Orthologous residues HIF2A (human): K503‑ub, HIF2A (mouse): K502‑ub, HIF2A (rat): K502‑ub Characterization Methods used to characterize site in vivo:  electrophoretic mobility shift, mutation of modification site, western blotting Relevant cell lines - cell types - tissues:  HEK293T (epithelial), HeLa (cervical) Cellular systems studied:  cell lines Species studied:  human Enzymes shown to modify site in vitro:  Type Enzyme UBIQUITIN LIGASE UBE2D1 (human) UBIQUITIN LIGASE VHL (human) Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes UBIQUITIN LIGASE VHL (human) transfection of wild-type enzyme

K512-ub - HIF2A (human) ▲

Modsite: FAMDTEAkDQCSTQT SwissProt Entrez-Gene Orthologous residues HIF2A (human): K512‑ub, HIF2A (mouse): R511‑ub, HIF2A (rat): K511‑ub Characterization Methods used to characterize site in vivo:  electrophoretic mobility shift, mutation of modification site, western blotting Relevant cell lines - cell types - tissues:  HEK293T (epithelial), HeLa (cervical) Cellular systems studied:  cell lines Species studied:  human Enzymes shown to modify site in vitro:  Type Enzyme UBIQUITIN LIGASE UBE2D1 (human) UBIQUITIN LIGASE VHL (human) Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes UBIQUITIN LIGASE VHL (human) transfection of wild-type enzyme